Do blood or marrow procedures ease joint soreness?

What have direct comparisons found?

Studies comparing marrow care with platelet-rich plasma found both knee groups felt less sore. Neither procedure gave clearly better relief than the other.

In those studies, platelet-rich plasma, or PRP, used blood platelets, small pieces involved in clotting, after concentrating them. Another comparison found both PRP and fat-care groups improved, with neither clearly ahead.

Those results came from knees, not hips or shoulders. You can't rely on them to predict relief in another joint.

At the Peoria office, QC Kinetix provides regenerative treatment options, or non-surgical procedures that use your blood. Its care team prepares them after examining your sore joint.

How can I spot an exaggerated promise?

Be wary of a promise to rebuild cartilage or repair a worn joint. Less soreness doesn't prove that worn tissue grew back.

Ask the clinic, "Did the study use the same blood, marrow, or fat procedure you're offering me?" Those procedures aren't interchangeable.

One person's success can be honest but still incomplete. It can't show whether the same person would have improved with exercise or cortisone.

A fair answer covers cost, recovery, and the chance of little change. You'll understand the choice better when those points are clear.

What result matters in daily life?

Choose one task that the sore joint keeps taking away. You may care most about stairs, sleep, golf, or a longer walk.

Write down how far you walk before the ache begins. Then note whether it settles by the next morning.

A pain score may fall even while stairs remain hard. Your chosen task gives the follow-up visit a clearer measure.

If the task doesn't get easier, discuss another form of care. Repeating the same procedure isn't the only answer.

Sources

1. In a 480-patient, four-arm, multicenter randomized phase 2/3 trial, none of three orthobiologic cell injections - autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction, or allogeneic umbilical cord tissue-derived mesenchymal stromal cells - was superior to any other, or to a corticosteroid injection control, on pain at 12 months.

   Mautner K, et al. — Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial. Nat Med, 2023. DOI: 10.1038/s41591-023-02632-w.

2. In a prospective randomized trial of 90 patients with Kellgren-Lawrence grade 1-3 knee osteoarthritis, bone marrow aspirate concentrate produced outcomes equivalent to - not better than - leukocyte-rich platelet-rich plasma through 24 months.

   Anz AW, et al. — Bone Marrow Aspirate Concentrate Is Equivalent to Platelet-Rich Plasma for the Treatment of Knee Osteoarthritis at 2 Years: A Prospective Randomized Trial. Am J Sports Med, 2022. DOI: 10.1177/03635465211072554.

3. A systematic review and meta-analysis of 27 Level I studies (1,042 PRP, 226 BMAC, 1,128 hyaluronic acid patients) found PRP and BMAC both outperformed hyaluronic acid on WOMAC, VAS and subjective IKDC scores - note the BMAC evidence base is roughly one fifth the size of the PRP one.

   Belk JW, et al. — Patients With Knee Osteoarthritis Who Receive Platelet-Rich Plasma or Bone Marrow Aspirate Concentrate Injections Have Better Outcomes Than Patients Who Receive Hyaluronic Acid: Systematic Review and Meta-analysis. Arthroscopy, 2023. DOI: 10.1016/j.arthro.2023.03.001.

4. A Bayesian network meta-analysis of 48 randomized trials covering 9,338 knees found hyaluronic acid and PRP significantly improved pain versus placebo, and that BMAC accounted for only 2.5 percent of the studied injections - the thinnest evidence base of the four comparators.

   Jawanda H, et al. — Platelet-Rich Plasma, Bone Marrow Aspirate Concentrate, and Hyaluronic Acid Injections Outperform Corticosteroids in Pain and Function Scores at a Minimum of 6 Months as Intra-Articular Injections for Knee Osteoarthritis: A Systematic Review and Network Meta-analysis. Arthroscopy, 2024. DOI: 10.1016/j.arthro.2024.01.037.

5. A 2024 systematic review of 8 Level I randomized trials in 937 patients found bone marrow aspirate concentrate improved pain and function versus baseline from one month, but the comparative advantage over other injections was inconsistent across timepoints.

   Han JH, et al. — Bone Marrow Aspirate Concentrate Injections for the Treatment of Knee Osteoarthritis: A Systematic Review of Randomized Controlled Trials. Orthop J Sports Med, 2024. DOI: 10.1177/23259671241296555.

6. In a randomized trial of 118 knee osteoarthritis patients followed for 2 years with serial MRI, a single microfragmented adipose tissue injection and a single PRP injection produced statistically and clinically similar improvement - and the imaging showed no structural advantage for either.

   Zaffagnini S, et al. — Microfragmented Adipose Tissue Versus Platelet-Rich Plasma for the Treatment of Knee Osteoarthritis: A Prospective Randomized Controlled Trial at 2-Year Follow-up. Am J Sports Med, 2022. DOI: 10.1177/03635465221115821.

7. A 2025 systematic review and meta-analysis of 6 randomized trials found microfragmented adipose tissue and PRP both reached the minimal clinically important difference on most outcomes to 12 months, with no clear superiority of the fat-derived preparation despite its higher price.

   Park YB, et al. — Microfragmented Adipose Tissue as an Alternative to Platelet-Rich Plasma for Intra-articular Injection in Knee Osteoarthritis: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Am J Sports Med, 2025. DOI: 10.1177/03635465251337759.

8. A randomized trial comparing commercially available systems in 71 patients found microfragmented adipose tissue equivalent to leukocyte-rich PRP on KOOS pain at 12 months.

   Baria M, et al. — Microfragmented Adipose Tissue Is Equivalent to Platelet-Rich Plasma for Knee Osteoarthritis at 12 Months Posttreatment: A Randomized Controlled Trial. Orthop J Sports Med, 2024. DOI: 10.1177/23259671241233916.

9. A 2025 meta-analysis of 73 double-blind placebo-controlled injection trials in 5,895 knee osteoarthritis patients found placebo responder rates above 50 percent at 1, 3 and 6 months, declining by 12 months - which is why any uncontrolled 'our patients improved' claim from a clinic is uninterpretable.

   Previtali D, et al. — Placebo response to intra-articular injections in knee osteoarthritis: magnitude, evolution over time, and influencing factors. A systematic review and meta-analysis with meta-regression. EFORT Open Rev, 2025. DOI: 10.1530/EOR-2025-0022.

10. FDA states in its consumer alert that the only FDA-approved stem cell products in the United States are blood-forming stem cells derived from umbilical cord blood, approved for disorders of the blood-forming system, and that NONE of these products - stem cells, stromal vascular fraction, umbilical cord blood, Wharton's jelly or amniotic fluid - has been approved for the treatment of any orthopedic condition, including osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain or shoulder pain.

    US Food and Drug Administration, Center for Biologics Evaluation and Research — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. , 2020.